^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation

Published date:
03/08/2022
Excerpt:
We assayed three DNA-damaging agents (cisplatin, dacarbazine, and lomustine), a topoisomerase inhibitor (camptothecin), and a microtubule inhibitor (paclitaxel). Following treatment with each of these drugs, both A375 and UACC903 cells overexpressing ROR2 presented reduced cell death...These results indicate that ROR2 promotes chemoresistance of melanoma cells to cytotoxic compounds with different mechanisms of action by inhibiting apoptosis.
DOI:
10.1186/s11658-022-00327-7